AstraZeneca presents superior progression-free survival for ...
First-line Durvalumab Improves Survival
PACIFIC Trial: Adjuvant Immunotherapy Improves Overall Survival ...
NSCLC Clinical Trials & Efficacy for IMFINZI® (durvalumab)
New data on PD-L1 inhibitor activity and determinants of outcomes ...
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell ...
Immunotherapy: once more at the cutting edge of progress ...
IMFINZI® (Durvalumab) Significantly Improves Overall Survival in ...
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell ...
Updated Results on PACIFIC Trial: Revise Who Should Receive ...
Overall Survival with Durvalumab after Chemoradiotherapy in Stage ...
durvalumab hashtag on Twitter
Checkpoint inhibition excels in all treatment lines - memoinoncology
david vicente baz på Twitter: "Very proud of our contribution to ...
Three-Year Overall Survival with Durvalumab after ...
Immunotherapy: analyses elucidating durvalumab & pembrolizumab ...
Patient-reported outcomes with durvalumab after chemoradiotherapy ...
NSCLC Clinical Trials & Efficacy for IMFINZI® (durvalumab)
Uživatel NEJM na Twitteru: „Original Article: Overall Survival ...
PACIFIC Trial Leads to Durvalumab Approval in United States ...
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
First-Line Combination Treatment with Durvalumab Plus Platinum
Imfinzi® significantly improves overall survival in Phase III ...
Overall Survival with Durvalumab after Chemoradiotherapy in Stage ...
PACIFIC: A double-blind, placebo-controlled phase III study of ...
